Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpSSG RMS 2005 Protocol for Nonmetastatic Rhabdomyosarcoma
NCT00379457Phase 3Unknown
- Sponsor
- European Paediatric Soft Tissue Sarcoma Study Group
- Start
- Jun 2006
- Primary completion
- May 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of vinorelbine, cyclophosphamide and doxorubicin in rhabdomyosarcoma (RMS) (4 arms), sponsored by European Paediatric Soft Tissue Sarcoma Study Group. Primary endpoints: Event-Free Survival at 5 years and Disease-Free Survival at 5 years. Status: unknown.
02
Drugs
vinorelbinecyclophosphamidedoxorubicin
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT00379457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379457.